Science
Immune Activation,
Only at the Region of Interest
Leveraging the Unique Environment of Tumors to Isolate Treatment Effect
Most tumors are persistently acidic due to metabolic reprogramming and extracellular space remodeling. Our Tumor Microenvironment Activated Therapeutics (T-MATE) employ an acidity-sensitive switching mechanism that enables strong therapeutic activities of immune cells against tumors but exponentially reduced activity against healthy cells.
Conditional Activation Serves to Widen Therapeutic Index
T-MATE technology greatly expands the target space of current and future platform therapeutics, such as T cell engagers, to cover both established and emerging tumor-associated antigens that are invariably expressed in healthy tissues.
